New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 19, 2013
07:08 EDTNLNKNewLink Genetics launches Phase 1 clinical trial of HyperAcute Immunotherapy
NewLink Genetics announced that it had launched a first in human Phase 1 clinical trial of HyperAcute Renal immunotherapy in patients with metastatic renal cell cancer. HyperAcute Renal Immunotherapy is comprised of two allogeneic renal cell cancer cell lines engineered to express the murine alpha GT gene. The Phase 1 dose-escalation study is designed primarily to determine the safety of HyperAcute Renal immunotherapy cells administered by intradermal injection in up to 20 patients with recurrent or refractory, metastatic clear-cell renal cancer.
News For NLNK From The Last 14 Days
Check below for free stories on NLNK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 7, 2014
07:27 EDTNLNKAmerican Association of Cancer Research to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use